<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

Newsroom

Press Releases

Our latest announcements

Biodesix to Present Data Supporting Proteomic-Based Immunotherapy Diagnostic Tests and AI Explainability in Diagnostic Tests at Society for Immunotherapy of Cancer Annual Meeting

Biodesix, Inc. today announced that the company will co-present with Genentech three posters at SITC Nov. 10–14, 2021 from research into diagnostic tests of treatment response of NSCLC patients to immune checkpoint inhibitor therapy.

Biodesix to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum

Biodesix, Inc. today announced CEO Scott Hutton will present in a fireside chat at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum being held virtually November 18, 2021.

Biodesix to Report Third Quarter 2021 Financial Results on November 15, 2021

Biodesix, Inc. today announced that it will release financial results for the third quarter ended September 30, 2021 before the open of trading on Monday, November 15.

Biodesix Announces New Data on Nodify Lung® Nodule Risk Assessment Testing at the CHEST 2021 Annual Meeting

Biodesix, Inc., a leading data-driven diagnostic solutions company, today announced that multiple data presentations will occur at the 2021 annual CHEST virtual conference.

Biodesix Announces Abstracts Presented During the IASLC 2021 World Conference on Lung Cancer

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that two abstracts highlighting proteomic and genomic data based on their diagnostic tests were presented at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC).

Biodesix DeSoto Laboratory Receives both ISO 13485:2016 Certification and Accreditation from the College of American Pathologists

Today Biodesix announced that the Accreditation Committee of the College of American Pathologists (CAP) and British Standards Institute (BSI) on behalf of International Organization for Standardization (ISO) recently awarded both CAP accreditation and ISO 13485:2016 certification to the Biodesix Laboratory located in DeSoto, Kansas, based on results of two independent inspections conducted by CAP and BSI inspectors.

Biodesix Announces Presentation on Novel Proteomic Techniques in Partnership with Seer

Biodesix and Seer to discuss combined efforts to utilize Seer Proteograph™ Product Suite to drive novel proteomic insights for translational research

Biodesix Announces

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the broad commercial launch of a SARS Cov-2 Neutralization Antibody Test (cPass™ Neutralization Test Kit, GenScript Inc.).

Biodesix Partners with Datavant to Enhance Value of Lung Cancer Databank

Biodesix Partners with Datavant to Enhance Value of Lung Cancer Databank

First Patient Enrolled in Biodesix and Addario Lung Cancer Medical Institute Study Aiming to Predict Patient Survival Using a Blood-based Biomarker

 Biodesix, Inc. and Addario Lung Cancer Medical Institute (ALCMI) today announced they will present on the progress of “Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy (BEACON-Lung).”

First 1 2 3 4 5 6 7 8 9 Last